Braftovi
Named-patient access overview. Braftovi is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Braftovi (encorafenib) is an oral selective BRAF kinase inhibitor originally developed by Array BioPharma and now marketed by Pfizer. The US Food and Drug Administration approved Braftovi in June 2018 in combination with binimetinib (Mektovi) for unresectable or metastatic BRAF V600E or V600K-mutant melanoma, in April 2020 in combination with cetuximab for BRAF V600E-mutant metastatic colorectal cancer after prior therapy, and in October 2023 in combination with binimetinib for BRAF V600E-mutant metastatic non-small cell lung cancer.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Braftovi
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Braftovi is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country deep-dive for Braftovi in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Braftovi
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.